littl known genom alter underli osteosarcoma perform genomewid high-resolut gene copi number analysi osteosarcoma sampl us compar genom hybrid cdna microarrai contain cdna clone 000 gene nineteen case amplif averag span contain gene numer region gain loss identifi boundari defin high resolut novel amplicon found 14q11 17q25 22q11-q13 earlier-known larg amplifi region detect 12q11-q15 8q24 6p12-p13 17p11-p13 sampl respect amplif 12q observ frequent case previous report previous known small amplicon 1p34-p36 1q21 19q13 21q22 least three case result implic tom1l2 cyp27b1 have role novel target 17p 12q amplicon respect detail www.helsinki.fi/cmg amplifi gene amplicon provid valuabl raw data silico studi
purpos telomer consist repeat nucleotid sequenc ttaggg shorten normal somat cell telomeras enzym elong telomer sequenc detect most human cancer usual normal somat cell littl known telomeras activ bone soft tissu tumor aim studi investig relationship telomeras activ clinic factor bone soft tissu tumor method telomeras activ measur us modifi telomer repeat amplif protocol trap assai 115 bone soft tissu tumor obtain through open biopsi resect result telomeras activ detect benign tumor malign tumor &lt 0.001 higher incid telomeras activ detect high-grade tumor low-grade tumor 0.002 cumul metastasi-free overal surviv telomeras-posit patient significantli wors telomeras-neg patient 0.045 0.048 conclus studi suggest telomeras activ associ tumor aggress us paramet predict prognosi patient malign bone soft tissu tumor
background osteosarcoma malign bone tumor consist cell abnorm cellular function osteosarcoma-deriv cell commonli us osteoblast model molecular composit osteosarcoma extracellular matrix ecm well character materi method compar three osteosarcoma cell line mg-63 sao-2 u-2 normal human osteoblast immunocytochemistri cellular characterist assess morphometr analysi prolifer kinet result investig osteosarcoma cell line exhibit heterogen label profil differ significantli normal osteoblast sao-2 cell reveal most matur osteoblast label profil u-2 cell neg most investig osteoblast marker conclus conclud osteosarcoma cell line exhibit characterist label profil produc differ compos extracellular matrix us attempt better character osteosarcoma well diagnosi
background glutam system fairli complex bioregul pathwai consist sever ionotrop glu receptor iglu.rs metabotrop glu receptor mglu.rs glu transport eaat glutamin synthetas metabol glutam glutamin materi method character mg-63 human osteoblast-like osteosarcoma cell regard mrna express nmda.r group iglu.rs mglu.rs eaat1 transport us specif primer detect rt-pcr result data confirm mrna express nr1 nr2a nr2b nr2d subunit nmda.r mrna mg-63 cell addit document first time mrna express nr3a eaat1 mglu.r1 mglu.r2 mglu.r3 mglur.4 mglu.r5 mglu.r8 mrna howev detect mrna express nr2c nr3b mglu.r6 mglu.r7 mrna conclus data suggest mg-63 cell us model studi possibl role glu beyond cn
background malign degre human chondrosarcoma difficult determin us histolog find assess express matrix metalloproteinas mmp disintegrin metalloproteinas adam thrombospondin motif adamtss tissu inhibitor metalloproteinas timp chondrosarcoma ascertain relationship histolog degre malign prognosi materi method chondrosarcoma case immunostain perform us antibodi mmp adamt timp result chondrosarcoma classifi group case base histolog malign grade iii respect target protein express chondrosarcoma posit correl &lt 0.05 exist immunostain score histolog grade protein except mmp strong correl &lt 0.01 mmp both adamtss timp correl exist prognosi immunostain score conclus target protein indic degre malign human chondrosarcoma
object explor prognost marker osteosarcoma method express p53 c-myc bcl-2 apoptosi index osteosarcoma specimen detect abc immunohistochemistri termin deoxynucleotidyl transferas tdt -mediat dutp-digoxigenin nick label tunel relationship gene express apoptosi correl patholog classif prognost factor analyz result neg correl express p53 c-myc bcl-2 protein close relat long term surviv patient relat patholog type tumor conclus express p53 c-myc bcl-2 protein us index predict progress prognosi osteosarcoma
purpos evalu differ surgic techniqu us treatment giant cell tumor bone effect rate local recurr patient method prospect studi fifti-two patient giant cell tumor gct bone treat nation cancer institut cairo univers 1998 2002 patient evalu clinic examin plain x-rai scan mri case biopsi taken case confirm diagnosi defin grade tumor patient underw surgic treatment includ curettag curettag combin cryosurgeri bone cement bone graft bone resect amput select surgic techniqu base site size lesion soft tissu involv intra- extra-compartment tumor grade recurr patient follow minimum twenti-four month result patient patient male patient femal male femal ratio 2.7 ag patient rang year mean ag 32.9 year base ennek's stage system patient stage patient stage &amp stage iib histopatholog examin case reveal giant cell tumor borderlin malign curettag alon done patient curettag bone cement patient curettag cryosurgeri bone graft patient curettag cryosurgeri bone cement patient resect patient amput patient mortal among case local recurr highest case treat curettag lowest case treat curettag cryosurgeri bone cement 16.6 conclus main primari treatment gct surgeri type depend preoper evalu includ clinic evalu involv site size tumor relat surround structur togeth plain x-rai scan mri indic tissu biopsi defin tumor grade curettag alon result high rate local recurr hand curettag adjuv cryosurgeri us bone cement bone graft give low rate local recurr resect recommend stage iib extrem larg lesion case resect result signific morbid proxim fibula flat bone amput preserv massiv recurr malign transform
